Efficacy and Safety of Docetaxel as a Second–Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate efficacy and safety of docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) at Naresuan University Hospital. Methods: The study was a survey study with retrospective data collection from medical records and electronic databases in patients with advanced NSCLC treated with first-line chemotherapy and receiving docetaxel as a second-line treatment during October 1, 2010 to June 30, 2016. Treatment outcomes were median–overall survival, progression–free survival, response rate and any grade toxicity. Results: From the total of 34 patients, efficacy was derived from that data of 27 patients. Median-overall survival after treatment with docetaxel was 10.13 months (95%CI 7.71-12.55). Progression-free survival was 3.47 months (95%CI 2.13-4.81). Two patients showed overall response, 10 with stable disease and 12 with progressive disease. Analysis of docetaxel safety in all patients revealed hematologic toxicities i.e., anemia in 31 patients, neutropenia in 20 patients, febrile neutropenia in 2 patients with one patient dead from this condition and thrombocytopenia in 1 patient. Common non-hematologic toxicities included fatigue (17 patients), mucositis (12 patients), nausea (10 patients) and vomiting (7 patients). Conclusion: Patients with advanced NSCLC and receiving docetaxel as a second line treatment had a comparable median-overall survival, progression-free survival and response rate to those reported in previous studies. Incidences of docetaxel toxicities, both hematologic and non–hematologic, were higher than those reported in previous studies.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Islami F, Torre LA, Jema A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 2015;4:327-38.
3. International agency for research on cancer. Lung cancer estimated incidence, mortality and prevalence worldwide in 2012 [online]. 2017 [cited Jul 9, 2017]. Available from: globocan.iarc.fr/Pages /fact_sheets_cancer.aspx.
4. National Cancer Institute. Hospital based cancer registry 2015. Bangkok: Pornsup Printing; 2017.
5. NCCN clinical practice guideline in oncology (NCCN guidelines). Non-small cell lung cancer v.7.2017 [online]. 2017 [cited Jul 9, 2017]. Available from: www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
6. Fossella FV, DeVore R, Kerr RN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small-cell lung cancer study group. J Clin Oncol 2000;18:2354-62.
7. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Water house DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front -line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8.
8. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-73.
9. Borghaei H1, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015;373:1627-39.
10. Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach J, Perrone F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008;3:430–40.
11. Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA 2017; 317:1844-53.
12. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci 2015;106:497–504.
13. Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zim mermann AH, et al. East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL). Cancer Res Treat 2016;48:1177-86.
14. Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 2016; 99: 186–93.
15. Nakamura Y, Kunitoh H, Kubota K, Sekine I, Yamamoto N, Tamura T, et al. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non–small cell lung cancer patients previously treated with platinum-based chemotherapy. Am J Clin Oncol 2003; 26: 459–64.
16. Mukohara T, Takeda K, Miyazaki M, Takifuji N, Terakawa K, Negoro S. Japanese experience with second-line chemotherapy with low-dose (60 mg/m2 ) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001; 48: 356-60.
